TDS Pharm Co (XKRX:464280) PE Ratio: 5.67 (As of Sep. 13, 2026) — 64% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:464280 TDS Pharm Co Ltd XKRX:464280
40 GF Score
Price ₩5,520.00
! 1 Warning Sign
View Full Analysis

What is TDS Pharm Co PE Ratio?

TDS Pharm Co XKRX:464280 40 PE Ratio is 5.67 as of Sep. 13, 2026, which is 64% below its 10-year median of 15.79. GuruFocus rates XKRX:464280 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-09-13), TDS Pharm Co's share price is ₩5520.00. TDS Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₩974.00. Therefore, TDS Pharm Co's PE Ratio for today is 5.67.

During the past 6 years, TDS Pharm Co's highest PE Ratio was 35.53. The lowest was 4.70. And the median was 15.79.

TDS Pharm Co's EPS (Diluted) for the three months ended in Jun. 2026 was ₩181.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₩974.00.

As of today (2026-09-13), TDS Pharm Co's share price is ₩5520.00. TDS Pharm Co's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₩972.72. Therefore, TDS Pharm Co's PE Ratio without NRI ratio for today is 5.67.

During the past 6 years, TDS Pharm Co's highest PE Ratio without NRI was 35.53. The lowest was 4.71. And the median was 16.09.

TDS Pharm Co's EPS without NRI for the three months ended in Jun. 2026 was ₩179.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was ₩972.72.

During the past 12 months, TDS Pharm Co's average EPS without NRI Growth Rate was 122.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was -4.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -50.00% per year.

During the past 6 years, TDS Pharm Co's highest 3-Year average EPS without NRI Growth Rate was -4.10% per year. The lowest was -66.70% per year. And the median was -56.70% per year.

TDS Pharm Co's EPS (Basic) for the three months ended in Jun. 2026 was ₩181.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₩974.00.

Back to Basics: PE Ratio


TDS Pharm Co  (XKRX:464280) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


TDS Pharm Co PE Ratio Related Terms


TDS Pharm Co PE Ratio Historical Data

* Premium members only.

The historical data trend for TDS Pharm Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TDS Pharm Co PE Ratio Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial N/A N/A N/A 16.49 12.19

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.19 16.54 12.19 8.73 6.50

XKRX:464280 vs LLY, JNJ, ABBV: PE Ratio Comparison

For the Drug Manufacturers - General subindustry, TDS Pharm Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TDS Pharm Co PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where TDS Pharm Co's PE Ratio falls into.


XKRX:464280
40GF Score
TDS Pharm Co Ltd XKRX:464280
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TDS Pharm Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

TDS Pharm Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=5520.00/974.000
=5.67

TDS Pharm Co's Share Price of today is ₩5520.00.
TDS Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩974.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 5.67 mean?
TDS Pharm Co (XKRX:464280) has a PE Ratio of 5.67 as of Sep. 13, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on TDS Pharm Co and its competitors. This is 64% below median its historical median of 15.79. Over the past decade, TDS Pharm Co's PE Ratio has ranged from 4.70 to 35.53.
Is TDS Pharm Co's PE Ratio too high?
TDS Pharm Co's current PE Ratio of 5.67 is 64% below median its 10-year median of 15.79. Over the past 10 years, this metric has ranged from a low of 4.70 to a high of 35.53. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's PE Ratio compare to LLY and JNJ?
TDS Pharm Co's PE Ratio of 5.67 can be compared against companies in the Drug Manufacturers industry. Historically, TDS Pharm Co's own PE Ratio has ranged from 4.70 to 35.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on TDS Pharm Co and its competitors. TDS Pharm Co's current PE Ratio is 5.67, which is 64% below median its own 10-year median of 15.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current PE Ratio of 5.67. The current PE Ratio is 5.67, which is 64% below median its 10-year median of 15.79. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current PE Ratio is 5.67 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TDS Pharm Co Business Description

Address 253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score

Get the complete analysis for XKRX:464280

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩5,520.00
Price